Operation Warp Speed Angles For Greater Role In Pfizer COVID-19 Vaccine Manufacturing
Government offers help securing supplies in return for another 100 million doses by Q2. That would mean abandoning Pfizer’s preferred arms-length relationship.
You may also be interested in...
Pfizer CEO Albert Bourla and HHS deputy chief of staff Paul Mango offer their perspectives in separate interviews promoting new books about the campaign to develop vaccines against COVID-19.
It’s counter-intuitive, but not signing a commercial contract with BioNTech and refusing US federal funding were two of several moves Pfizer made to speed up development of its COVID-19 vaccine, CEO Albert Bourla says. Now it’s looking to supply low- and middle-income countries.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.